市場調査レポート

商品コード

1172345

世界のライソゾーム病治療薬市場：産業調査報告書、成長動向と競合分析 (2022年～2028年)

Global Lysosomal Disease Treatment Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

出版日: 2022年12月15日 | 発行: QYResearch

| ページ情報: 英文 112 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 5,600 879,984円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Multi User License)

USD 8,400 1,319,976円

レポートPDFを5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise User License)

USD 11,200 1,759,968円

レポートPDFを企業内すべての方にご使用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

ご注意事項 :

本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

当レポートは、ライソゾーム病治療薬 (Lysosomal Disease Treatment) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

調査範囲
市場分析：タイプ別
- 世界のライソゾーム病治療薬の市場規模成長率：タイプ別: 2017 VS 2021 VS 2028
- Hematopoietic Stem Cell Transplantation
- Enzyme Replacement Therapy
- Substrate Reduction
- Chaperone Therapies
市場：用途別
- 世界のライソゾーム病治療薬用途別の市場成長率: 2017 VS 2021 VS 2028
- Hospitals
- Clinics
- Stem Cell Transplant Center
- Research Organizations
- Others
調査目的
対象期間

第2章市場展望

世界のライソゾーム病治療薬市場規模 (2017-2028)
ライソゾーム病治療薬世界の主要地域における市場規模: 2017 VS 2021 VS 2028
世界のライソゾーム病治療薬市場規模：地域別 (2017-2022)
世界のライソゾーム病治療薬市場規模予測：地域別 (2023-2028)
世界のトップライソゾーム病治療薬国別の市場規模ランキング

第3章ライソゾーム病治療薬企業別の競争率

世界のライソゾーム病治療薬の収益：企業別
- 世界のライソゾーム病治療薬の収益：企業別 (2017-2022)
- 世界のライソゾーム病治療薬企業別の市場シェア (2017-2022)
世界のライソゾーム病治療薬の市場シェア：企業タイプ別 (Tier 1, Tier 2, ・ Tier 3)
対象企業: ランキング別ライソゾーム病治療薬の収益
世界のライソゾーム病治療薬市場集中度
- 世界のライソゾーム病治療薬市場集中度 (CR5 ・ HHI)
- 世界の上位10・上位5企業：ライソゾーム病治療薬の収益 2021
世界のライソゾーム病治療薬の主要企業の本社および事業エリア
主要企業ライソゾーム病治療薬の製品ソリューションおよびサービス
市場参入時期：ライソゾーム病治療薬市場
M&A, 拡張計画

第4章世界のライソゾーム病治療薬内訳データ：タイプ別

世界のライソゾーム病治療薬実績と収入タイプ別 (2017-2022)
世界のライソゾーム病治療薬の収益予測：タイプ別 (2023-2028)

第5章世界のライソゾーム病治療薬内訳データ：用途別

世界のライソゾーム病治療薬の市場規模実績：用途別 (2017-2022)
世界のライソゾーム病治療薬の市場規模予測：用途別 (2023-2028)

第6章北米

北米のライソゾーム病治療薬収益：企業別 (2020-2022)
北米のライソゾーム病治療薬の収益：タイプ別 (2017-2028)
北米のライソゾーム病治療薬の収益：用途別 (2017-2028)
北米のライソゾーム病治療薬の収益：国別 (2017-2028)
- 米国
- カナダ

第7章欧州

欧州のライソゾーム病治療薬収益：企業別 (2020-2022)
欧州のライソゾーム病治療薬の収益：タイプ別 (2017-2028)
欧州のライソゾーム病治療薬の収益：用途別 (2017-2028)
欧州のライソゾーム病治療薬の収益：国別 (2017-2028)
- ドイツ
- フランス
- 英国
- イタリア
- ロシア

第8章アジア太平洋

アジア太平洋のライソゾーム病治療薬収益：企業別 (2020-2022)
アジア太平洋のライソゾーム病治療薬の収益：タイプ別 (2017-2028)
アジア太平洋のライソゾーム病治療薬の収益：用途別 (2017-2028)
アジア太平洋のライソゾーム病治療薬の収益：地域別 (2017-2028)
- 中国
- 日本
- 韓国
- インド
- オーストラリア
- 台湾
- インドネシア
- タイ
- マレーシア
- フィリピン
- ベトナム

第9章ラテンアメリカ

ラテンアメリカのライソゾーム病治療薬収益：企業別 (2020-2022)
ラテンアメリカのライソゾーム病治療薬の収益：タイプ別 (2017-2028)
ラテンアメリカのライソゾーム病治療薬の収益：用途別 (2017-2028)
ラテンアメリカのライソゾーム病治療薬の収益：国別 (2017-2028)
- メキシコ
- ブラジル
- アルゼンチン

第10章中東・アフリカ

中東・アフリカのライソゾーム病治療薬収益：企業別 (2020-2022)
中東・アフリカのライソゾーム病治療薬の収益：タイプ別 (2017-2028)
中東・アフリカのライソゾーム病治療薬の収益：用途別 (2017-2028)
中東・アフリカのライソゾーム病治療薬の収益：国別 (2017-2028)
- トルコ
- サウジアラビア
- U.A.E

第11章企業プロファイル

Astellas Pharma
Astrazeneca
Actelion Pharmaceuticals Ltd.
Eli Lilly and Co.
Merck & Co.
Novo Nordisk A/S
Shire
Pfizer
Sanofi
BioMarin

第12章ライソゾーム病治療薬市場動向

ライソゾーム病治療薬市場トレンド
ライソゾーム病治療薬市場の促進要因
ライソゾーム病治療薬市場の課題
ライソゾーム病治療薬市場の抑制要因

第13章市場調査結果と結論

第14章付録

図表

List of Tables

Table 1. Global Lysosomal Disease Treatment Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Hematopoietic Stem Cell Transplantation
Table 3. Key Players of Enzyme Replacement Therapy
Table 4. Key Players of Substrate Reduction
Table 5. Key Players of Chaperone Therapies
Table 6. Global Lysosomal Disease Treatment Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 7. Global Lysosomal Disease Treatment Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 8. Global Lysosomal Disease Treatment Revenue by Region (2017-2022) & (US$ Million)
Table 9. Global Lysosomal Disease Treatment Revenue Market Share by Region (2017-2022)
Table 10. Global Lysosomal Disease Treatment Revenue by Players (2017-2022) & (US$ Million)
Table 11. Global Lysosomal Disease Treatment Market Share by Players (2017-2022)
Table 12. Global Top Lysosomal Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lysosomal Disease Treatment as of 2021)
Table 13. Ranking of Global Top Lysosomal Disease Treatment Companies by Revenue (US$ Million) in 2021
Table 14. Global 5 Largest Players Market Share by Lysosomal Disease Treatment Revenue (CR5 and HHI) & (2017-2022)
Table 15. Key Players Headquarters and Area Served
Table 16. Key Players Lysosomal Disease Treatment Product Solution and Service
Table 17. Date of Key Manufacturers Enter into Lysosomal Disease Treatment Market
Table 18. Mergers & Acquisitions, Expansion Plans
Table 19. Global Lysosomal Disease Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 20. Global Lysosomal Disease Treatment Revenue Market Share by Type (2017-2022)
Table 21. Global Lysosomal Disease Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 22. Global Lysosomal Disease Treatment Revenue Market Share by Type (2023-2028)
Table 23. Global Lysosomal Disease Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 24. Global Lysosomal Disease Treatment Revenue Market Share by Application (2017-2022)
Table 25. Global Lysosomal Disease Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 26. Global Lysosomal Disease Treatment Revenue Market Share by Application (2023-2028)
Table 27. North America Lysosomal Disease Treatment Revenue by Company (2020-2022) & (US$ Million)
Table 28. North America Lysosomal Disease Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 29. North America Lysosomal Disease Treatment Revenue by Type (2023-2028) & (US$ Million)
Table 30. North America Lysosomal Disease Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 31. North America Lysosomal Disease Treatment Revenue by Application (2023-2028) & (US$ Million)
Table 32. North America Lysosomal Disease Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 33. North America Lysosomal Disease Treatment Revenue by Country (2023-2028) & (US$ Million)
Table 34. Europe Lysosomal Disease Treatment Revenue by Company (2020-2022) & (US$ Million)
Table 35. Europe Lysosomal Disease Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 36. Europe Lysosomal Disease Treatment Revenue by Type (2023-2028) & (US$ Million)
Table 37. Europe Lysosomal Disease Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 38. Europe Lysosomal Disease Treatment Revenue by Application (2023-2028) & (US$ Million)
Table 39. Europe Lysosomal Disease Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 40. Europe Lysosomal Disease Treatment Revenue by Country (2023-2028) & (US$ Million)
Table 41. Asia Pacific Lysosomal Disease Treatment Revenue by Company (2020-2022) & (US$ Million)
Table 42. Asia Pacific Lysosomal Disease Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 43. Asia Pacific Lysosomal Disease Treatment Revenue by Type (2023-2028) & (US$ Million)
Table 44. Asia Pacific Lysosomal Disease Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 45. Asia Pacific Lysosomal Disease Treatment Revenue by Application (2023-2028) & (US$ Million)
Table 46. Asia Pacific Lysosomal Disease Treatment Revenue by Region (2017-2022) & (US$ Million)
Table 47. Asia Pacific Lysosomal Disease Treatment Revenue by Region (2023-2028) & (US$ Million)
Table 48. Latin America Lysosomal Disease Treatment Revenue by Company (2020-2022) & (US$ Million)
Table 49. Latin America Lysosomal Disease Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 50. Latin America Lysosomal Disease Treatment Revenue by Type (2023-2028) & (US$ Million)
Table 51. Latin America Lysosomal Disease Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 52. Latin America Lysosomal Disease Treatment Revenue by Application (2023-2028) & (US$ Million)
Table 53. Latin America Lysosomal Disease Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 54. Latin America Lysosomal Disease Treatment Revenue by Country (2023-2028) & (US$ Million)
Table 55. Middle East and Africa Lysosomal Disease Treatment Revenue by Company (2020-2022) & (US$ Million)
Table 56. Middle East and Africa Lysosomal Disease Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 57. Middle East and Africa Lysosomal Disease Treatment Revenue by Type (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Lysosomal Disease Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Lysosomal Disease Treatment Revenue by Application (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Lysosomal Disease Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Lysosomal Disease Treatment Revenue by Country (2023-2028) & (US$ Million)
Table 62. Astellas Pharma Company Details
Table 63. Astellas Pharma Business Overview
Table 64. Astellas Pharma Lysosomal Disease Treatment Product and Services
Table 65. Astellas Pharma Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022) & (US$ Million)
Table 66. Astellas Pharma Lysosomal Disease Treatment SWOT Analysis
Table 67. Astellas Pharma Recent Developments
Table 68. Astrazeneca Company Details
Table 69. Astrazeneca Business Overview
Table 70. Astrazeneca Lysosomal Disease Treatment Product and Services
Table 71. Astrazeneca Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022) & (US$ Million)
Table 72. Astrazeneca Lysosomal Disease Treatment SWOT Analysis
Table 73. Astrazeneca Recent Developments
Table 74. Actelion Pharmaceuticals Ltd. Company Details
Table 75. Actelion Pharmaceuticals Ltd. Business Overview
Table 76. Actelion Pharmaceuticals Ltd. Lysosomal Disease Treatment Product and Services
Table 77. Actelion Pharmaceuticals Ltd. Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022) & (US$ Million)
Table 78. Actelion Pharmaceuticals Ltd. Lysosomal Disease Treatment SWOT Analysis
Table 79. Actelion Pharmaceuticals Ltd. Recent Developments
Table 80. Eli Lilly and Co. Company Details
Table 81. Eli Lilly and Co. Business Overview
Table 82. Eli Lilly and Co. Lysosomal Disease Treatment Product and Services
Table 83. Eli Lilly and Co. Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022) & (US$ Million)
Table 84. Eli Lilly and Co. Lysosomal Disease Treatment SWOT Analysis
Table 85. Eli Lilly and Co. Recent Developments
Table 86. Merck & Co. Company Details
Table 87. Merck & Co. Business Overview
Table 88. Merck & Co. Lysosomal Disease Treatment Product and Services
Table 89. Merck & Co. Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022) & (US$ Million)
Table 90. Merck & Co. Lysosomal Disease Treatment SWOT Analysis
Table 91. Merck & Co. Recent Developments
Table 92. Novo Nordisk A/S Company Details
Table 93. Novo Nordisk A/S Business Overview
Table 94. Novo Nordisk A/S Lysosomal Disease Treatment Product and Services
Table 95. Novo Nordisk A/S Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022) & (US$ Million)
Table 96. Novo Nordisk A/S Lysosomal Disease Treatment SWOT Analysis
Table 97. Novo Nordisk A/S Recent Developments
Table 98. Shire Company Details
Table 99. Shire Business Overview
Table 100. Shire Lysosomal Disease Treatment Product and Services
Table 101. Shire Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022) & (US$ Million)
Table 102. Shire Lysosomal Disease Treatment SWOT Analysis
Table 103. Shire Recent Developments
Table 104. Pfizer Company Details
Table 105. Pfizer Business Overview
Table 106. Pfizer Lysosomal Disease Treatment Product and Services
Table 107. Pfizer Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022) & (US$ Million)
Table 108. Pfizer Lysosomal Disease Treatment SWOT Analysis
Table 109. Pfizer Recent Developments
Table 110. Sanofi Company Details
Table 111. Sanofi Business Overview
Table 112. Sanofi Lysosomal Disease Treatment Product and Services
Table 113. Sanofi Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022) & (US$ Million)
Table 114. Sanofi Lysosomal Disease Treatment SWOT Analysis
Table 115. Sanofi Recent Developments
Table 116. BioMarin Company Details
Table 117. BioMarin Business Overview
Table 118. BioMarin Lysosomal Disease Treatment Product and Services
Table 119. BioMarin Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022) & (US$ Million)
Table 120. BioMarin Lysosomal Disease Treatment SWOT Analysis
Table 121. BioMarin Recent Developments
Table 122. Lysosomal Disease Treatment Market Trends
Table 123. Lysosomal Disease Treatment Market Drivers
Table 124. Lysosomal Disease Treatment Market Challenges
Table 125. Lysosomal Disease Treatment Market Restraints
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Lysosomal Disease Treatment Sales Market Share by Type: 2021 VS 2028
Figure 2. Hematopoietic Stem Cell Transplantation Features
Figure 3. Enzyme Replacement Therapy Features
Figure 4. Substrate Reduction Features
Figure 5. Chaperone Therapies Features
Figure 6. Global Lysosomal Disease Treatment Sales Market Share by Application: 2021 VS 2028
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Stem Cell Transplant Center Case Studies
Figure 10. Research Organizations Case Studies
Figure 11. Others Case Studies
Figure 12. Lysosomal Disease Treatment Report Years Considered
Figure 13. Global Lysosomal Disease Treatment Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Lysosomal Disease Treatment Market Size 2017-2028 (US$ Million)
Figure 15. Global Lysosomal Disease Treatment Market Size Market Share by Region: 2021 VS 2028
Figure 16. Global Lysosomal Disease Treatment Revenue Market Share by Region in 2017 VS 2022
Figure 17. Global Top 10 Lysosomal Disease Treatment Countries Ranking by Market Size (US$ Million) in 2021
Figure 18. Global Lysosomal Disease Treatment Market Share by Players in 2021
Figure 19. Global Top Lysosomal Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lysosomal Disease Treatment as of 2021)
Figure 20. The Top 10 and 5 Players Market Share by Lysosomal Disease Treatment Revenue in 2021
Figure 21. North America Lysosomal Disease Treatment Revenue Market Share by Company in 2021
Figure 22. North America Lysosomal Disease Treatment Revenue Market Share by Type (2017-2028)
Figure 23. North America Lysosomal Disease Treatment Revenue Market Share by Application (2017-2028)
Figure 24. North America Lysosomal Disease Treatment Revenue Share by Country (2017-2028)
Figure 25. U.S. Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 26. Canada Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 27. Europe Lysosomal Disease Treatment Revenue Market Share by Company in 2021
Figure 28. Europe Lysosomal Disease Treatment Revenue Market Share by Type (2017-2028)
Figure 29. Europe Lysosomal Disease Treatment Revenue Market Share by Application (2017-2028)
Figure 30. Europe Lysosomal Disease Treatment Revenue Share by Country (2017-2028)
Figure 31. Germany Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 32. France Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 33. U.K. Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 34. Italy Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 35. Russia Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 36. Asia Pacific Lysosomal Disease Treatment Revenue Market Share by Company in 2021
Figure 37. Asia Pacific Lysosomal Disease Treatment Revenue Market Share by Type (2017-2028)
Figure 38. Asia Pacific Lysosomal Disease Treatment Revenue Market Share by Application (2017-2028)
Figure 39. Asia Pacific Lysosomal Disease Treatment Revenue Share by Region (2017-2028)
Figure 40. China Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 41. Japan Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 42. South Korea Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 43. India Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 44. Australia Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 45. Taiwan Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 46. Indonesia Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 47. Thailand Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 48. Malaysia Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 49. Philippines Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 50. Vietnam Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 51. Latin America Lysosomal Disease Treatment Revenue Market Share by Company in 2021
Figure 52. Latin America Lysosomal Disease Treatment Revenue Market Share by Type (2017-2028)
Figure 53. Latin America Lysosomal Disease Treatment Revenue Market Share by Application (2017-2028)
Figure 54. Latin America Lysosomal Disease Treatment Revenue Share by Country (2017-2028)
Figure 55. Mexico Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 56. Brazil Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 57. Argentina Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 58. Middle East and Africa Lysosomal Disease Treatment Revenue Market Share by Company in 2021
Figure 59. Middle East and Africa Lysosomal Disease Treatment Revenue Market Share by Type (2017-2028)
Figure 60. Middle East and Africa Lysosomal Disease Treatment Revenue Market Share by Application (2017-2028)
Figure 61. Middle East and Africa Lysosomal Disease Treatment Revenue Share by Country (2017-2028)
Figure 62. Turkey Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 63. Saudi Arabia Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 64. U.A.E Lysosomal Disease Treatment Revenue (2017-2028) & (US$ Million)
Figure 65. Astellas Pharma Revenue Growth Rate in Lysosomal Disease Treatment Business (2017-2022)
Figure 66. Astrazeneca Revenue Growth Rate in Lysosomal Disease Treatment Business (2017-2022)
Figure 67. Actelion Pharmaceuticals Ltd. Revenue Growth Rate in Lysosomal Disease Treatment Business (2017-2022)
Figure 68. Eli Lilly and Co. Revenue Growth Rate in Lysosomal Disease Treatment Business (2017-2022)
Figure 69. Merck & Co. Revenue Growth Rate in Lysosomal Disease Treatment Business (2017-2022)
Figure 70. Novo Nordisk A/S Revenue Growth Rate in Lysosomal Disease Treatment Business (2017-2022)
Figure 71. Shire Revenue Growth Rate in Lysosomal Disease Treatment Business (2017-2022)
Figure 72. Pfizer Revenue Growth Rate in Lysosomal Disease Treatment Business (2017-2022)
Figure 73. Sanofi Revenue Growth Rate in Lysosomal Disease Treatment Business (2017-2022)
Figure 74. BioMarin Revenue Growth Rate in Lysosomal Disease Treatment Business (2017-2022)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed

This research report focuses on the Lysosomal Disease Treatment Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

1 Report Overview

1.1 Study Scope
1.2 Market Analysis by Type
- 1.2.1 Global Lysosomal Disease Treatment Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
- 1.2.2 Hematopoietic Stem Cell Transplantation
- 1.2.3 Enzyme Replacement Therapy
- 1.2.4 Substrate Reduction
- 1.2.5 Chaperone Therapies
1.3 Market by Application
- 1.3.1 Global Lysosomal Disease Treatment Market Growth Rate by Application: 2017 VS 2021 VS 2028
- 1.3.2 Hospitals
- 1.3.3 Clinics
- 1.3.4 Stem Cell Transplant Center
- 1.3.5 Research Organizations
- 1.3.6 Others
1.4 Study Objectives
1.5 Years Considered

2 Market Perspective

2.1 Global Lysosomal Disease Treatment Market Size (2017-2028)
2.2 Lysosomal Disease Treatment Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.3 Global Lysosomal Disease Treatment Market Size by Region (2017-2022)
2.4 Global Lysosomal Disease Treatment Market Size Forecast by Region (2023-2028)
2.5 Global Top Lysosomal Disease Treatment Countries Ranking by Market Size

3 Lysosomal Disease Treatment Competitive by Company

3.1 Global Lysosomal Disease Treatment Revenue by Players
- 3.1.1 Global Lysosomal Disease Treatment Revenue by Players (2017-2022)
- 3.1.2 Global Lysosomal Disease Treatment Market Share by Players (2017-2022)
3.2 Global Lysosomal Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Lysosomal Disease Treatment Revenue
3.4 Global Lysosomal Disease Treatment Market Concentration Ratio
- 3.4.1 Global Lysosomal Disease Treatment Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Top 10 and Top 5 Companies by Lysosomal Disease Treatment Revenue in 2021
3.5 Global Lysosomal Disease Treatment Key Players Head office and Area Served
3.6 Key Players Lysosomal Disease Treatment Product Solution and Service
3.7 Date of Enter into Lysosomal Disease Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Global Lysosomal Disease Treatment Breakdown Data by Type

4.1 Global Lysosomal Disease Treatment Historic Revenue by Type (2017-2022)
4.2 Global Lysosomal Disease Treatment Forecasted Revenue by Type (2023-2028)

5 Global Lysosomal Disease Treatment Breakdown Data by Application

5.1 Global Lysosomal Disease Treatment Historic Market Size by Application (2017-2022)
5.2 Global Lysosomal Disease Treatment Forecasted Market Size by Application (2023-2028)

6 North America

6.1 North America Lysosomal Disease Treatment Revenue by Company (2020-2022)
6.2 North America Lysosomal Disease Treatment Revenue by Type (2017-2028)
6.3 North America Lysosomal Disease Treatment Revenue by Application (2017-2028)
6.4 North America Lysosomal Disease Treatment Revenue by Country (2017-2028)
- 6.4.1 U.S.
- 6.4.2 Canada

7 Europe

7.1 Europe Lysosomal Disease Treatment Revenue by Company (2020-2022)
7.2 Europe Lysosomal Disease Treatment Revenue by Type (2017-2028)
7.3 Europe Lysosomal Disease Treatment Revenue by Application (2017-2028)
7.4 Europe Lysosomal Disease Treatment Revenue by Country (2017-2028)
- 7.4.1 Germany
- 7.4.2 France
- 7.4.3 U.K.
- 7.4.4 Italy
- 7.4.5 Russia

8 Asia Pacific

8.1 Asia Pacific Lysosomal Disease Treatment Revenue by Company (2020-2022)
8.2 Asia Pacific Lysosomal Disease Treatment Revenue by Type (2017-2028)
8.3 Asia Pacific Lysosomal Disease Treatment Revenue by Application (2017-2028)
8.4 Asia Pacific Lysosomal Disease Treatment Revenue by Region (2017-2028)
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 South Korea
- 8.4.4 India
- 8.4.5 Australia
- 8.4.6 Taiwan
- 8.4.7 Indonesia
- 8.4.8 Thailand
- 8.4.9 Malaysia
- 8.4.10 Philippines
- 8.4.11 Vietnam

9 Latin America

9.1 Latin America Lysosomal Disease Treatment Revenue by Company (2020-2022)
9.2 Latin America Lysosomal Disease Treatment Revenue by Type (2017-2028)
9.3 Latin America Lysosomal Disease Treatment Revenue by Application (2017-2028)
9.4 Latin America Lysosomal Disease Treatment Revenue by Country (2017-2028)
- 9.4.1 Mexico
- 9.4.2 Brazil
- 9.4.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Lysosomal Disease Treatment Revenue by Company (2020-2022)
10.2 Middle East and Africa Lysosomal Disease Treatment Revenue by Type (2017-2028)
10.3 Middle East and Africa Lysosomal Disease Treatment Revenue by Application (2017-2028)
10.4 Middle East and Africa Lysosomal Disease Treatment Revenue by Country (2017-2028)
- 10.4.1 Turkey
- 10.4.2 Saudi Arabia
- 10.4.3 U.A.E

11 Company Profiles

11.1 Astellas Pharma
- 11.1.1 Astellas Pharma Company Details
- 11.1.2 Astellas Pharma Business Overview
- 11.1.3 Astellas Pharma Lysosomal Disease Treatment Products and Services
- 11.1.4 Astellas Pharma Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022)
- 11.1.5 Astellas Pharma Lysosomal Disease Treatment SWOT Analysis
- 11.1.6 Astellas Pharma Recent Developments
11.2 Astrazeneca
- 11.2.1 Astrazeneca Company Details
- 11.2.2 Astrazeneca Business Overview
- 11.2.3 Astrazeneca Lysosomal Disease Treatment Products and Services
- 11.2.4 Astrazeneca Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022)
- 11.2.5 Astrazeneca Lysosomal Disease Treatment SWOT Analysis
- 11.2.6 Astrazeneca Recent Developments
11.3 Actelion Pharmaceuticals Ltd.
- 11.3.1 Actelion Pharmaceuticals Ltd. Company Details
- 11.3.2 Actelion Pharmaceuticals Ltd. Business Overview
- 11.3.3 Actelion Pharmaceuticals Ltd. Lysosomal Disease Treatment Products and Services
- 11.3.4 Actelion Pharmaceuticals Ltd. Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022)
- 11.3.5 Actelion Pharmaceuticals Ltd. Lysosomal Disease Treatment SWOT Analysis
- 11.3.6 Actelion Pharmaceuticals Ltd. Recent Developments
11.4 Eli Lilly and Co.
- 11.4.1 Eli Lilly and Co. Company Details
- 11.4.2 Eli Lilly and Co. Business Overview
- 11.4.3 Eli Lilly and Co. Lysosomal Disease Treatment Products and Services
- 11.4.4 Eli Lilly and Co. Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022)
- 11.4.5 Eli Lilly and Co. Lysosomal Disease Treatment SWOT Analysis
- 11.4.6 Eli Lilly and Co. Recent Developments
11.5 Merck & Co.
- 11.5.1 Merck & Co. Company Details
- 11.5.2 Merck & Co. Business Overview
- 11.5.3 Merck & Co. Lysosomal Disease Treatment Products and Services
- 11.5.4 Merck & Co. Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022)
- 11.5.5 Merck & Co. Lysosomal Disease Treatment SWOT Analysis
- 11.5.6 Merck & Co. Recent Developments
11.6 Novo Nordisk A/S
- 11.6.1 Novo Nordisk A/S Company Details
- 11.6.2 Novo Nordisk A/S Business Overview
- 11.6.3 Novo Nordisk A/S Lysosomal Disease Treatment Products and Services
- 11.6.4 Novo Nordisk A/S Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022)
- 11.6.5 Novo Nordisk A/S Lysosomal Disease Treatment SWOT Analysis
- 11.6.6 Novo Nordisk A/S Recent Developments
11.7 Shire
- 11.7.1 Shire Company Details
- 11.7.2 Shire Business Overview
- 11.7.3 Shire Lysosomal Disease Treatment Products and Services
- 11.7.4 Shire Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022)
- 11.7.5 Shire Lysosomal Disease Treatment SWOT Analysis
- 11.7.6 Shire Recent Developments
11.8 Pfizer
- 11.8.1 Pfizer Company Details
- 11.8.2 Pfizer Business Overview
- 11.8.3 Pfizer Lysosomal Disease Treatment Products and Services
- 11.8.4 Pfizer Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022)
- 11.8.5 Pfizer Lysosomal Disease Treatment SWOT Analysis
- 11.8.6 Pfizer Recent Developments
11.9 Sanofi
- 11.9.1 Sanofi Company Details
- 11.9.2 Sanofi Business Overview
- 11.9.3 Sanofi Lysosomal Disease Treatment Products and Services
- 11.9.4 Sanofi Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022)
- 11.9.5 Sanofi Lysosomal Disease Treatment SWOT Analysis
- 11.9.6 Sanofi Recent Developments
11.10 BioMarin
- 11.10.1 BioMarin Company Details
- 11.10.2 BioMarin Business Overview
- 11.10.3 BioMarin Lysosomal Disease Treatment Products and Services
- 11.10.4 BioMarin Lysosomal Disease Treatment Revenue in Lysosomal Disease Treatment Business (2017-2022)
- 11.10.5 BioMarin Lysosomal Disease Treatment SWOT Analysis
- 11.10.6 BioMarin Recent Developments

12 Lysosomal Disease Treatment Market Dynamics

12.1 Lysosomal Disease Treatment Market Trends
12.2 Lysosomal Disease Treatment Market Drivers
12.3 Lysosomal Disease Treatment Market Challenges
12.4 Lysosomal Disease Treatment Market Restraints

13 Research Findings and Conclusion

14 Appendix

14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.2 Data Source
14.2 Author Details

世界のライソゾーム病治療薬市場：産業調査報告書、成長動向と競合分析 (2022年～2028年)

Global Lysosomal Disease Treatment Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

目次

第1章レポート概要

第2章市場展望

第3章ライソゾーム病治療薬企業別の競争率

第4章世界のライソゾーム病治療薬内訳データ：タイプ別

第5章世界のライソゾーム病治療薬内訳データ：用途別

第6章北米

第7章欧州

第8章アジア太平洋

第9章ラテンアメリカ

第10章中東・アフリカ

第11章企業プロファイル

第12章ライソゾーム病治療薬市場動向

第13章市場調査結果と結論

第14章付録

List of Tables

List of Figures

TABLE OF CONTENTS

1 Report Overview

2 Market Perspective

3 Lysosomal Disease Treatment Competitive by Company

4 Global Lysosomal Disease Treatment Breakdown Data by Type

5 Global Lysosomal Disease Treatment Breakdown Data by Application

6 North America

7 Europe

8 Asia Pacific

9 Latin America

10 Middle East and Africa

11 Company Profiles

12 Lysosomal Disease Treatment Market Dynamics

13 Research Findings and Conclusion

14 Appendix

世界のライソゾーム病治療薬市場：産業調査報告書、成長動向と競合分析 (2022年～2028年)

Global Lysosomal Disease Treatment Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

目次

第1章 レポート概要

第2章 市場展望

第3章 ライソゾーム病治療薬 企業別の競争率

第4章 世界のライソゾーム病治療薬 内訳データ：タイプ別

第5章 世界のライソゾーム病治療薬 内訳データ：用途別

第6章 北米

第7章 欧州

第8章 アジア太平洋

第9章 ラテンアメリカ

第10章 中東・アフリカ

第11章 企業プロファイル

第12章 ライソゾーム病治療薬 市場動向

第13章 市場調査結果と結論

第14章 付録

List of Tables

List of Figures

TABLE OF CONTENTS

1 Report Overview

2 Market Perspective

3 Lysosomal Disease Treatment Competitive by Company

4 Global Lysosomal Disease Treatment Breakdown Data by Type

5 Global Lysosomal Disease Treatment Breakdown Data by Application

6 North America

7 Europe

8 Asia Pacific

9 Latin America

10 Middle East and Africa

11 Company Profiles

12 Lysosomal Disease Treatment Market Dynamics

13 Research Findings and Conclusion

14 Appendix

第1章レポート概要

第2章市場展望

第3章ライソゾーム病治療薬企業別の競争率

第4章世界のライソゾーム病治療薬内訳データ：タイプ別

第5章世界のライソゾーム病治療薬内訳データ：用途別

第6章北米

第7章欧州

第8章アジア太平洋

第9章ラテンアメリカ

第10章中東・アフリカ

第11章企業プロファイル

第12章ライソゾーム病治療薬市場動向

第13章市場調査結果と結論

第14章付録